KINARX
KinaRx LLC is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia, with an emphasis on the treatment of drug resistant tumors.
KINARX
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
West Lafayette, Indiana, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
2.13 M USD
Current Employees Featured
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - KinaRx
More informations about "KinaRx"
Company Overview - KinaRx
Company Overview Early stage biotechnology company developing novel kinase inhibitors for cancer. Inspired by the desire to treat patients we are relentlessly focused on developing the …See details»
KinaRx - Crunchbase Company Profile & Funding
Organization. KinaRx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. KinaRx is a biotech firm focuses on the …See details»
KinaRx Company Profile 2024: Valuation, Funding & Investors
KinaRx General Information Description. Operator of a biotechnology company intended to develop novel kinase inhibitors for treating cancer patients. The company's technology aims at …See details»
KinaRx, LLC - VentureRadar
KinaRx is a biotechnology company developing novel kinase inhibitors for cancer. Our proprietary technology, generates unique compounds potently active against protein kinases with a focus …See details»
Our Science – KinaRx
Our Science A rapid discovery platform Identify KIPS (Kinase Privileged Scaffolds) and use Multicomponent rapid chemical synthesis reactions to generate novel highly effective kinase …See details»
KinaRx - Funding, Financials, Valuation & Investors - Crunchbase
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia. Search Crunchbase. ... How much funding has this organization …See details»
New technology targets cancer, other diseases, and …
Jul 18, 2019 KinaRx was founded by Sintim, its chief scientific officer, along with M. Javad Aman, Rena Lapidus, Ashkan Emadi, Frederick Holtsberg and Joe O'Neill. It is based in Rockville, Maryland.See details»
$400,000 SBIR grant fast-tracks new approach to …
Jun 18, 2020 WEST LAFAYETTE, Ind. – A novel approach to treating lung and thyroid cancers is moving closer to clinical trials. A $399,933 SBIR Phase I grant from the National Cancer Institute to KinaRx, a Purdue University-affiliated …See details»
KinaRx - Updates, News, Events, Signals & Triggers - Crunchbase
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
New technology targets cancer, other diseases, and …
Jul 18, 2019 KinaRx has licensed through the Purdue Research Foundation Office of Technology Commercialization a series of drug compounds that have shown promise in treating patients who have a recurrence of acute myeloid …See details»
$2 million SBIR grant fast-tracks cancer drug | EurekAlert!
Jun 3, 2020 A $1,999,998 SBIR Phase I/II grant from the National Institute of Cancer to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform …See details»
Acute myeloid leukemia discovery tackles drug-resistant gene …
Jun 20, 2024 Sintim is also the co-founder of KinaRx, and will continue to work closely with Kapur, a scientific advisory board member at the company. “This academic-industry …See details»
$400,000 SBIR grant fast-tracks new approach | EurekAlert!
Jun 19, 2020 A $399,933 SBIR Phase I grant from the National Cancer Institute to KinaRx, a Purdue University-affiliated startup, will help to advance a novel platform aimed at producing …See details»
KinaRx receives SBIR grant to speed up clinical trials for AML and ...
Jun 3, 2020 A $1,999,998 SBIR Phase I/II grant from the National Institute of Cancer to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform …See details»
Third line treatment of drug resistant FLT3-positive acute myeloid ...
Jun 1, 2020 KinaRx has developed a novel class of orally bioavailable 5-substituted aminonapthyridine TKIs that are active against secondary mutated FLT3 resistant to the 1st …See details»
Pipeline - KinaRx
Pipeline FLT3 mutant AML Activating mutations in FLT3 are found in 30% of Acute Myeloid Leukemia (AML) and associated with poor prognosis. Approved FLT3 inhibitors show clinical …See details»
KinaRx - Contacts, Employees, Board Members, Advisors & Alumni …
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
KRX-101, a Novel FLT3 Inhibitor, Potently Active Against Resistant
Nov 29, 2018 Introduction. Presence of FLT3-ITD gene mutations is a poor prognostic factor in acute myeloid leukemia (AML).Midostaurin, a multikinase inhibitor, is approved for treatment of …See details»
The Kinark Foundation - Kinark
The Kinark Foundation offers hope and help by raising funds and awareness to support the mission of Kinark – helping children and youth with complex needs achieve better life outcomes.See details»